Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
|Articles|December 1, 1998
Oncology NEWS International
- Oncology NEWS International Vol 7 No 12
- Volume 7
- Issue 12
Advisory Panel Recommends Approval of Vysis HER2 Test
ROCKVILLE, Md-The FDA’s Hematology and Pathology Devices Panel voted unanimously to recommend that the agency grant conditional approval to Vysis, Inc.’s PathVysion HER-2 DNA Probe Kit to detect and quantify the HER2 gene in breast cancer patients. Based on Vysis’ fluorescence in situ hybridization (FISH) technology, the test for the HER2 gene was developed as a predictive marker for determining a patient’s response to doxorubicin-based chemotherapy.
Advertisement
ROCKVILLE, MdThe FDAs Hematology and Pathology Devices Panel voted unanimously to recommend that the agency grant conditional approval to Vysis, Inc.s PathVysion HER-2 DNA Probe Kit to detect and quantify the HER2 gene in breast cancer patients. Based on Vysis fluorescence in situ hybridization (FISH) technology, the test for the HER2 gene was developed as a predictive marker for determining a patients response to doxorubicin-based chemotherapy.
Articles in this issue
almost 28 years ago
Long-Term Adjuvant Tamoxifen Urged for Low-Risk Breast Canceralmost 28 years ago
EORTC DCIS Study Confirms Recurrence Reduction With RTalmost 28 years ago
James Cancer Center Joins NCCN Outcomes Databasealmost 28 years ago
Managed Care Sees Need for National Guidelines, Accreditationalmost 28 years ago
Drinking Tea After Smoking May Reduce Oxidative Stressalmost 28 years ago
Use Special Skills, Tools to Assess Pain in Children, Elderlyalmost 28 years ago
Good Response Rates With Radiolabeled Anti-CD20 MoAB in NHLalmost 28 years ago
Tobacco Industry Settles With Statesalmost 28 years ago
Komen Foundation 1998 Awards Honor Leaders in Fight Against Breast CancerAdvertisement
Related to this article
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5